UltrasoundObstetGynecol2022;60:59–67
PublishedonlineinWileyOnlineLibrary(wileyonlinelibrary.com).DOI:10.1002/uog.24885.
ThisisanopenaccessarticleunderthetermsoftheCreativeCommonsAttribution-NonCommercial-NoDerivsLicense,whichpermitsuseand
distributioninanymedium,providedtheoriginalworkisproperlycited,theuseisnon-commercialandnomodificationsoradaptationsaremade.
Exome sequencing as first-tier test for fetuses with severe
central nervous system structural anomalies
Y. YARON1,2# , V. OFEN GLASSNER1#, A. MORY1, N. ZUNZ HENIG1, A. KUROLAP1,
A. BAR SHIRA1, D. BRABBING GOLDSTEIN1,3, D. MAROM1,2, L. BEN SIRA2,4,
H. BARIS FELDMAN1,2, G. MALINGER2,3 , K. KRAJDEN HARATZ2,3# and A. RECHES1,3#
1PrenatalGeneticDiagnosisUnit,GeneticsInstitute,TelAvivSouraskyMedicalCenter,TelAviv,Israel;2SacklerFacultyofMedicine,
TelAvivUniversity,TelAviv,Israel;3DivisionofObstetricUltrasound,LisMaternityHospital,TelAvivSouraskyMedicalCenter,
TelAviv,Israel;4RadiologyDepartment,TelAvivSouraskyMedicalCenter,TelAviv,Israel
KEYWORDS: brain; central nervous system; chromosomal microarray; copy-number variant; exome sequencing; fetus;
malformation;prenataldiagnosis
CONTRIBUTION CMA-negative cases were analyzed using ES, which
detectedP/LPsequencevariantsin38/86(44%).Among
Whatarethenovelfindingsofthiswork?
recurrentcases(i.e.caseswithapreviouslyaffectedpreg-
In this study of 114 cases that underwent termination of
nancy), the incidence of P/LP sequence variants was
pregnancyfollowingthedetectionofamajorcentralner-
non-significantly higher compared with non-recurrent
vous system anomaly, chromosomal microarray analysis
ones (12/19 (63%) vs 26/67 (39%); P=0.06). Among
(CMA) detected causative copy-number variants (CNVs)
the 38 cases with an ES diagnosis, 20 (53%) were inher-
in10%offetuses.Among86CMA-negativecases,exome
itedandcarriedasignificantriskofrecurrence.Reanalysis
sequencing (ES) detected causative sequence variants in
of 10 CMA-positive cases by ES demonstrated that the
44%. The ES bioinformatics pipeline also detected 13 of
bioinformaticspipelineusedforsequencevariantanalysis
thecausativeandpreviouslyknownnon-causativeCNVs.
also detected all P/LP CNVs, as well as three previously
Whataretheclinicalimplicationsofthiswork? knownnon-causativeCNVs.
OurdatasuggestthatEScouldbeconsideredasafirst-tier
Conclusions Inourstudy,ESprovidedahighdiagnostic
clinicaldiagnostictestintheprenataldiagnosisoffetuses
yield (>50%) in fetuses with severe CNS structural
withmajorCNSanomalies,asitcandetectbothsequence
anomalies,whichmayhavebeenpartlyduetothehighly
variantsandCNVs.
selected case series that included post-TOP cases from
a specialist referral center. These data suggest that ES
ABSTRACT may be considered as a first-tier test for the prenatal
diagnosis of major fetal CNS anomalies, detecting both
Objective Prenatally detected central nervous system
P/LP sequence variants and CNVs. This is of particular
(CNS) anomalies present a diagnostic challenge. In
importance given the time constraints of an ongoing
this study, we compared the diagnostic yield of exome
pregnancyandtheriskofrecurrenceinfuturepregnancies.
sequencing (ES) and chromosomal microarray analysis
© 2022 The Authors. Ultrasound in Obstetrics &
(CMA)infetuseswithamajorCNSanomaly.
Gynecology published by John Wiley & Sons Ltd on
Methods This was a retrospective study of 114 cases behalfofInternationalSocietyofUltrasoundinObstetrics
referred for genetic evaluation following termination of andGynecology.
pregnancy (TOP) due to a major CNS anomaly detected
on prenatal ultrasound. All fetuses were first analyzed
by CMA. All CMA-negative cases were offered ES.
INTRODUCTION
CMA-positivecaseswerereanalyzedusingEStoassessits
abilitytodetectcopy-numbervariants(CNVs). Approximately 2–5% of pregnancies present with a
Results CMAidentifiedapathogenicorlikelypathogenic sonographically detected fetal anomaly that warrants
(P/LP) CNV in 11/114 (10%) cases. Eighty-six further evaluation1. These anomalies range from an
Correspondence to: Prof. Y. Yaron, Prenatal Genetic Diagnosis Unit, Genetics Institute, Tel Aviv Sourasky Medical Center, Weitzman 6,
TelAviv,6423906,Israel(e-mail:yuvaly@tlvmc.gov.il)
#Y.Y.andV.O.G.arejointfirstauthors;K.K.H.andA.R.arejointseniorauthors.
Accepted:9February2022
© 2022TheAuthors.UltrasoundinObstetrics&GynecologypublishedbyJohnWiley&SonsLtd ORIGINAL PAPER
onbehalfofInternationalSocietyofUltrasoundinObstetricsandGynecology.
60 Yaronetal.
apparentlyisolateddefecttomultisystemmalformations. anomaly affected only one brain developmental process
Akaryotypeabnormalityisfoundin8–10%ofcaseswith were described separately according to the category,
such an anomaly that undergo diagnostic testing, and a as determined by consensus: malformation of cortical
copy-numbervariant(CNV)isidentifiedinanadditional development, midline anomaly (corpus callosal, septal,
6%, leaving the majority of cases without a specific holoprosencephaly), brain cyst (subependymal, arach-
geneticdiagnosis1–4.Thisisbecausemanyanomalieshave noid),midbrain–hindbrainmalformationandneuraltube
monogenic etiology (i.e. a single-gene disorder caused defect. These cases were defined as ‘isolated severe CNS
by a point mutation or small insertion/deletion)1. The malformations’. Of note, mild isolated findings, such as
detectionofsuchgeneticaberrationsrequiresmuchhigher mild ventriculomegaly, were not included in this study.
resolution,whichcanbeachievedonlybynext-generation Hydrocephalus secondary to aqueductal stenosis was
sequencingtechnology,suchastargetedmultigenepanels, consideredamidbrain–hindbrainanomaly.Braindamage
exome sequencing (ES) or whole-genome sequencing. ES was not considered an isolated anomaly if the insult
issometimesappliedasasecond-orthird-tierdiagnostic affecteddifferentregionsofthebrainsimultaneously.
test in selected cases of fetal anomaly. Recent work has
shown that ES provides an additional yield of 5–57%
Geneticanalysis
overthat ofchromosomalmicroarrayanalysis(CMA) in
theprenatalsetting5–9. As routine practice, all cases of fetal anomaly subjected
Thecentralnervoussystem(CNS)isaffectedin9%of to termination of pregnancy underwent DNA extraction
fetalmalformationsbutaccountsforasmuchasone-third from amniotic fluid or fetal blood (obtained during feti-
of all pregnancy terminations due to fetal anomaly. cide). Extraction from blood always produced sufficient
Moreover, CNS abnormalities are often diagnosed late DNA. Direct extraction following amniocentesis usually
in pregnancy10. When applying conventional methods suffices for both CMA and ES, but, occasionally, cell
(karyotyping followed by CMA or CMA alone) to the cultureisneededifbothanalysesaretobeperformed.
diagnosisoffetalCNSanomalies,theestimateddiagnostic All cases were first analyzed by CMA, some prior
yielddoesnotexceed20%11–13.Thus,morethan80%of
to termination of pregnancy and some as part of
casesremainwithoutageneticdiagnosis,probablyowing the post-termination work-up. CMA was performed
toalargeproportionofcaseshavingmonogenicetiology. using a CytoScan 750K array (Affymetrix, Santa Clara,
In this study, we compared the diagnostic yield of ES CA, USA). The platform is composed of 550000
and CMA in fetuses with a major CNS anomaly leading non-polymorphic CNV probes and more than 200000
to termination of pregnancy. In addition, we sought to single-nucleotide polymorphism probes, with an average
determine the diagnostic yield for specific categories of resolution of 100kb. Analysis was performed using
CNSanomaly. the Chromosome Analysis Suite (ChAS) software v 3.1
(Affymetrix). Detected CNVs were classified as either
pathogenic (P), likely pathogenic (LP), benign, likely
METHODS
benign or as a variant of uncertain clinical significance
Thiswasaretrospectivestudyofallcasesreferredtoour (VOUS), according to the updated American College of
institution for genetic evaluation following termination Medical Genetics and Genomics (ACMG) and Clinical
of pregnancy due to a major fetal CNS anomaly GenomeResource(ClinGen)guidelines15.Agenomicmap
between2014and2021.Allpatientsunderwentdetailed from the University of California, Santa Cruz Genome
neurosonographic examination in orthogonal planes, Browser16 was used to map the locations of CNVs
as described previously14, at the Division of Obstetric and gene content according to build hg19/GRCh37. The
Ultrasound at the Lis Maternity Hospital, Tel Aviv Database of Genomic Variants17, as well as our internal
Sourasky Medical Center, Tel Aviv, Israel, which is a database,providedcatalogsofstructuralvariationsfound
tertiary referral center for fetal CNS anomalies. Patients inhealthycontrols.
then received comprehensive genetic counseling at the AllpatientswithanegativeCMAresultreceivedfurther
PrenatalGeneticDiagnosisUnitoftheGeneticsInstitute. genetic counseling and were offered ES trio analysis.
Following counseling, patients signed a standard clinical CMA-positivecaseswerereanalyzedusingEStoassessits
consentformforgenetictesting. abilitytodetectCNVs.DNAsamplesfromparents–fetus
Clinical data were retrieved retrospectively from trios underwent ES. The first 15 cases were outsourced
electronic medical records at the Genetics Institute toexternalaccreditedclinicallaboratories(Centogeneor
and prenatal ultrasound reports, as well as fetal brain CeGat, Germany). Cases 1–5 have been reported previ-
magnetic resonance imaging (MRI) data, were also ously18.Themajority(71initiallyevaluatedcasesand10
retrieved when available. All patient information was reanalyzedcases(84%))weresequencedandanalyzedat
anonymized. Families with recurrent CNS anomalies theTelAvivSouraskyGenomicsCenter.Sequencingwas
were considered as a single case. Cases were further performed on a NovaSeq 6000 sequencer (Illumina, San
subcategorized according to clinical findings. Cases with Diego,CA,USA)with100-bppaired-endreads.
multiple brain anomalies were categorized as ‘complex’, The entire bioinformatics pipeline from FASTQ files
while cases with additional extracranial anomalies to the final report was performed using the Franklin
were categorized as ‘multisystem’. Cases in which the genetic analysis platform (Genoox, Tel Aviv, Israel).
© 2022TheAuthors.UltrasoundinObstetrics&GynecologypublishedbyJohnWiley&SonsLtd UltrasoundObstetGynecol2022;60:59–67.
onbehalfofInternationalSocietyofUltrasoundinObstetricsandGynecology.
ExomesequencinginfetuseswithCNSanomalies 61
FASTQ files were aligned against the hg19/GRCh37 Patients with CNS
reference genome using BWA v 0.7.1619. Variant calling anomaly
(n=114)
for single nucleotide variants (SNVs) and indels was
performed using Genome Analysis Toolkit v 4.0.12.020
Normal CMA Abnormal CMA
andFreeBayesv1.1.021. (n=103) (n=11)
In addition to SNVs and small indels, the Franklin Declined ES
(n=13)
pipeline also detects CNVs using Genoox proprietary Insufficient fetal
Consented to ES
DNA
CNV-caller, which mainly utilizes coverage information (n=90)
(n=1)
and is expected to detect CNVs down to a resolution of Insufficient fetal
DNA
two exons in the heterozygous state and a single exon in (n=4)
ES performed Reanalysis by ES
thehomozygousstate22. (n=86) (n=10)
Sequence variant annotation, classification and prior-
itization, as well as CNV classification, were performed
Figure1Flowchartsummarizinggenetictestingworkflowincases
using Franklin according to ACMG guidelines15,23. thatunderwentterminationofpregnancyfollowingdetectionofa
The bioinformatics analysis was based solely on the fetalcentralnervoussystem(CNS)anomalyonultrasound.CMA,
prenatal phenotype. The minimal criteria for a sample chromosomalmicroarrayanalysis;ES,exomesequencing.
to be included in the analysis were average coverage
of 70× and at least 98% of variants with a quality
score above 40. Family-case analysis was prepared sequence variants were detected in 38/86 (44%) cases
considering different possible modes of inheritance. The (Table2). In nine (10%) additional cases, a VOUS with
variants were filtered, retaining the following: (1) rare potentialclinicalrelevancewasreported(TableS1).Inthe
variants with minor allele frequency <5%; (2) protein- remaining39cases,novariantwasreported(TableS2).
altering variants; (3) variants in coding regions or those The incidence of P/LP sequence variants was
up to 10bp from splice junctions; (4) variants with non-significantly higher among the recurrent cases (i.e.
a high or medium aggregated quality score. Variants cases with a previously affected pregnancy) compared
were prioritized by Franklin based on their degree of with non-recurrent cases (12/19 (63%) vs 26/67 (39%),
pathogenicity and clinical information transcribed into χ-square statistic=3.56, P=0.06). No difference in the
HumanPhenotypeOntology(HPO)terms24. incidence of P/LP sequence variants was noted between
caseswithananomalylimitedtotheCNSandthosewith
multisystemabnormalities(24/54(44%)vs14/32(44%)).
Statisticalanalysis
Of the cases with an ES diagnosis, 20/38 (53%) were
Statistical analysis was performed using Social Science inheritedandcarriedasignificantriskofrecurrence(eight
Statistics25;P<0.05wasconsideredtoindicatestatistical autosomalrecessive(AR),fiveautosomaldominant(AD)
significance. andsevenX-linkedcases).Theremaining18caseshada
de-novoheterozygousvariantinanADorX-linkedgene.
To evaluate the detection rate in different clinical
RESULTS
categories, cases were subcategorized (Table3). The
highestdiagnosticyieldwasobservedincasescategorized
The study included 114 consecutive cases following ter-
as having multisystem (14/32 (44%)) and complex
minationofpregnancyduetoamajorfetalCNSanomaly.
brain (14/24 (58%)) anomalies. Cases with specific
MRI was performed in 25 cases at a median gestational
isolated brain anomalies were too few to draw definitive
age of 30weeks. Postmortem confirmation of the imag-
ing findings was obtained in 21 cases. All fetuses were conclusions. As a group, cases with isolated severe
first analyzed by CMA. Eleven (10%) cases had a P/LP CNS malformation had the lowest diagnostic yield (7/21
CNV (Figure1), most of which were deletions harbor- (33%)),asdidcaseswithbraindamage(3/9(33%)).
inghaploinsufficientgenes(Table1).Theseincludednine Toassesswhetherthebioinformaticspipelineemployed
de-novo CNVs, one case of triploidy and a case with for SNV analysis (Franklin) can detect CNVs, we
a terminal deletion of 3p26.1 and a terminal duplica- performed ES analysis in 10 of the 11 cases detected by
tionof8q24.3,compatiblewithanunbalancedreciprocal CMA(Cases9,11,15,17,18,27,47,53,63and71).In
translocation. In the latter case, parental karyotyping Case54,therewasinsufficientDNAforESanalysis.Three
revealedthatthemothercarriedabalancedtranslocation additional cases had incidental, non-causative CNVs
46,XX,t(3;8)(p26.1;q24.3), conferring a significant risk (Cases 16, 86 and 107). The CNV size ranged from
ofrecurrenceinsubsequentpregnancies. 335kb to 19080kb, and all CNVs were called correctly
Of the 103 CMA-negative cases, 13 patients declined bythebioinformaticsanalysispipeline.TriploidyofCase
further analysis by ES and, in four other cases, there 15 was not detected directly by the pipeline. However,
wasinsufficientfetalDNAforfurtheranalysis(Figure1). the homozygous/heterozygous ratio, a quality control
The remaining 86 cases underwent ES analysis. These metric,was0.34,farbelowthenormalrange(0.45–0.80),
included 82 fetus–parents trios, one solo fetal analysis, suggestingsuchanabnormality.
one fetus–mother duo and two quatros including both In summary, 96 cases had undergone ES analysis (86
parents and two affected fetuses. P/LP (Class V/IV) CMA-negative cases and 10 reanalyzed CMA-positive
© 2022TheAuthors.UltrasoundinObstetrics&GynecologypublishedbyJohnWiley&SonsLtd UltrasoundObstetGynecol2022;60:59–67.
onbehalfofInternationalSocietyofUltrasoundinObstetricsandGynecology.
62 Yaronetal.
ylamonametsyssuovrenlartneclateffosesac411gnoma)AMC(sisylanayarraorcimlamosomorhcybdetcetedstnairavrebmun-ypoc)PL(cinegohtapylekildna)P(cinegohtaP1elbaT
AMC
evitasuaC
noitacfiissalc
)bk(eziS
setanidrooccimoneG
)s(eneg
tluserAMC
yrogetaC
sgnidnfilacinilC
esaC
P
038
3.22q41rra
2XTO
*3.22q41led
niarbxelpmoC
,llawralucirtnevralugerri,CCcitsalpsyD
9
1×)32574475–66561665(
aisalpopyhenitnop
P
533
3.31p61rra
PBBERC
*3.31p61led
niarbxelpmoC
DCMfosngis,CCcitsalpsyD
11
1×)4465004–2050563(
P
3×)X22–1(rra
elpitluM
†ydiolpirT
metsysitluM
,DSV,aisalpopyhralleberec,ylahpecorciM
51
,hcamotsdetaived,syendikcinegohce,ASRA
reddalbllagtnesba
P
08091
3.41p33.51p5rra
elpitluM
*3.41p33.51p5led
niarbxelpmoC
,noitaclusdeyaled,CCcitsalpsyD
71
1×)13670891–1(
aisalpopyhralleberecotnop
P
9041
3.41q5rra
C2FEM
*3.41q5led
niarbxelpmoC
lamronba,imalahtdesuf,sisenegaCC
81
1×)14047688–22556278(
niarbdim
PL
8182
33.42q21rra
elpitluM
*33.42q21led
metsysitluM
,snrohroiretnalamronba,sisenegsydnaimreV
72
1×)265777331–629859031(
yendikcivlep,DCMfosngis
P
6621
1.22q8rra
1SSDTP
*1.22q8led
metsysitluM
sngis,CCcitsalpsyd,MVdlim,ylahpecorcaM
74
1×)86408489–48141279(
htworgrevo,DCMfo
P
9559
2.12q13.31q3rra
elpitluM
*2.12q13.31q3led
metsysitluM
,sllawralucirtnevralugerri,CCcitsalpsyD
35
1×)920127521–976161611(
fosngis,ygolohprommetsniarblamronba
saercnapralunna,DCM
P
1385
1.52q42q3rra
1CIZ
‡1.52q42q3led
BHBM
aisalpopyhnaimreV
45
1×)920881941–640753341(
P
6913
2.31p3.31p71rra
1B1HAFAP
*2.31p3.31p71led
niarbxelpmoC
DCMfosngis,CCcitsalpsyd,MVcirtemmysA
36
1×)6544304–057838(
)1SIL(
P
1051/1835
1.62p3rra
elpitluM
§*3.42q8pud/1.62p3led
metsysitluM
gnoltrohs,DCMfosngis,CCcitsalpsyD
17
/1×)6023445–19816(
soinmardyhogilo,RGUI,senob
3.42q8rra
3×)0177592641–838497441(
.gnicneuqesemoxeybnoitamrfinocrofANDtneicfifusnI‡.oitarytisogyzoreteh/ytisogyzomohwoloteudgnicneuqesemoxeybdetcepsusydiolpirT†.gnicneuqesemoxeybdetcetedoslanoiteleD*
–niarbdim,BHBM;noitcirtserhtworgeniretuartni,RGUI;musollacsuproc,CC;yretranaivalcbusthgirtnarreba,ASRA.)3.42q;2.62p()8;3(t,XX64noitacolsnartlacorpicerdecnalablanretaM§
.tcefedlatpesralucirtnev,DSV;ylagemolucirtnev,MV;tnempolevedlacitrocfonoitamroflam,DCM;noitamroflamniarbdnih
© 2022TheAuthors.UltrasoundinObstetrics&GynecologypublishedbyJohnWiley&SonsLtd UltrasoundObstetGynecol2022;60:59–67.
onbehalfofInternationalSocietyofUltrasoundinObstetricsandGynecology.
ExomesequencinginfetuseswithCNSanomalies 63
yarraorcimlamosomorhcnotluserevitagenahtiwylamonametsyssuovrenlartneclateffosesac68gnomagnicneuqesemoxeybdetcetedstnairav)PL(cinegohtapylekildna)P(cinegohtaP2elbaT
sisylana
ecnatirehnI
nrettap
ytisogyZ
noitacfiissalcGMCAtnairaV
)s(tnairaV
eneG
yrogetaclacinilC
sgnidnfignigamI
esaC
DA
)ovoned(teh
)2SP,2MP,2PP,1MP,5PP(P
;A>G5011.c:4.900600_MN
A1ABUT
niarbxelpmoC
,aisalpopyhralleberec,airygyhcap,MV
1
)rhT963alA(.p
CCcitsalpsyd
RLX
)tam(imeh
)4PP,3PP,5MP,2MP,1MP(PL
;T>C499.c:3.850931_MN
XRA
niarbxelpmoC
DCMesuffidfosngis,sisenegaCC
2
)syC233grA(.p
DA
)tam(teh
)4PP,2PP,3PP,2MP,1MP(PL
;T>C827.c:4.680600_MN
3BBUT
metsysitluM
,DCMfosngis,CCcitsalpsyD
3
)ueL342orP(.p
,snrohroiretnacirtemmysa
msiroletopyh
RA
moh
)5PP,2MP,1SVP(P
;T>C2701.c:3.483300_MN
1KRV
niarbxelpmoC
deyaled,CCcitsalpsyd,ylahpecorciM
5
)*853grA(.p
aisalpopyhralleberec,noitaclus
DA
)ovoned(teh
)2MP,2SP,1SVP(P
;led9832.c:5.072500_MN
2ILG
metsysitluM
laixatsop,tsyccirehpsimehretnI
82
)3*sforP797rhT(.p
ylytcadylop
RA
moh
)5PP,2MP,1SVP(P
;led055.c:3.813000_MN
2XEP
ylamonaenildiM
desuf,CCcitsalpsyd,EPH
53
)8*sflaV481syC(.p
reklaW–ydnaD,nolahpecneid
noitamroflam
DA
)tam(teh
)2MP,1SVP(PL
;T>C7711.c:5.653510_MN
BIRCS
DTN
II-epyTiraihC,elecogninemoleyM
04
)*393nlG(.p
noitamroflam
DA
)ovoned(teh
)2PP,3PP,2MP,1MP(PL
;C>T9011.c:5.550200_MN
PAFG
niarbxelpmoC
,ygolohpromSBlamronba,MVereveS
24
)orP073ueL(.p
DCMfosngis
RA
tehpmoc
)4PP,3PP,2MP,1SVP(P
;A>C5401.c:4.171700_MN
1TMOP
niarbxelpmoC
depahs-Z,CCcitsalpsyd,MVereveS
64
)rhT943orP(.p
,aisalpopyhralleberec,SBcitsalpopyh
;pud7612.c:4.171700_MN
DCMfosngis,sisonetslatcudeuqa
)8*sfylG327psA(.p
RLX
)tam(imeh
)5PP,2MP,1SVP(P
;T>C3541.c:5.524000_MN
MAC1L
metsysitluM
latcudeuqa,CCcitsalpsyd,MVereveS
94
)*584grA(.p
ralleberec,SBdepahs-Z,sisonets
bmuhtdetcudda,aisalpopyh
RA
moh
)4PP,2MP,1SVP(P
;led3321_2321.c:6.608230_MN
2TNGMOP
metsysitluM
latcudeuqa,CCcitsalpsyd,MVereveS
05
)01*sfgrA114nlG(.p
ralleberec,SBdepahs-Z,sisonets raluco,DCMfosngis,aisalpopyh
tnemhcatedlaniter,ylamona
RA
moh
)5PP,2MP,1SVP(P
;led6423_3423.c:5.154810_MN
JPNEC
metsysitluM
,DCMfosngis,ylahpecorciM
55
)8*sfgrA1801reS(.p
msiroletopyh
DA
)tam(teh
)4PP,2MP,1SVP(PL
)?1teM(.p;C>T2.c:4.512500_MN
CCD
metsysitluM
,sevaellatpeskciht,sisenegaCClaitraP
16
AUS,metsysgnitcellocelbuod
DA
)tam(teh
)4PP,2PP,3PP,2MP,1MP(PL
;T>C1411.c:2.212392100_MN
BBUT
DCM
DCMfosngis,CCcitsalpsyd,MV
26
)ehP183ueL(.p
RA
moh
)4PP,1MP,3PP,2MP(PL
;C>T1712.c:4.004000_MN
2CCRE
niarbxelpmoC
egral,tsyccirehpsimehretni,sisenegaCC
56
)rhT427teM(.p
SBlamronba,DCMfosngis,CH
DA
)ovoned(teh
)2SP,2MP,1SVP(P
:)4.845000_MN(9.610000_CN
2CST
metsysitluM
samoymodbahrcaidrac,srebutniarB
86
A>G1+184.c
.revodeunitnoC
© 2022TheAuthors.UltrasoundinObstetrics&GynecologypublishedbyJohnWiley&SonsLtd UltrasoundObstetGynecol2022;60:59–67.
onbehalfofInternationalSocietyofUltrasoundinObstetricsandGynecology.
64 Yaronetal.
deunitnoC2elbaT
ecnatirehnI
nrettap
ytisogyZ
noitacfiissalcGMCAtnairaV
)s(tnairaV
eneG
yrogetaclacinilC
sgnidnfignigamI
esaC
DA
)ovoned(teh
)4PP,2MP,2SP,1SVP(P
:)5.548100_MN(11.310000_CN
1A4LOC
niarbxelpmoC
,tsyccirehpsimehretni,sisenegaCC
07
C>G1-883.c
aisalpopyhenitnop,DCMfosngis
DLX
)tam(imeh
)4PP,3PP,4MP,2MP,1MP(PL
;A>G373.c:2.655011100_MN
ANLF
metsysitluM
lamronba,DCMfosngis,CCcitsalpsyD
27
)nsA521psA(.p
ylytcadnyseot,evlavcitroa
DA
)tap(teh
)1PP,4PP,4MP,2MP(PL
;led8614_1514.c:4.648100_MN
2A4LOC
egamadniarB
VIedarGHVI
37
)led6831ylG_1831alA(.p
DLX
)tam(imeh
)4PP,3PP,2PP,1PP,2MP(PL
;A>G08921.c:7.704130_MN
1EWUH
niarbxelpmoC
DCMfosngis,CCcitsalpsyD
67
)nlG7234grA(.p
RLX
)tam(imeh
)3PP,2MP,4PP,5PP(PL
;T>C1853.c:5.524000_MN
MAC1L
niarbxelpmoC
,snrohlatnorflamronba,CCcitsalpsyD
77
)ueL4911reS(.p
,sisonetslatcudeuqa,SBdepahs-Z
aisalpsydnaimrev
RLX
)tam(teh
)5PP,4PP,1PP,2MP(PL
;C>T0104.c:3.606400_MN
1FAT
metsysitluM
naimrev,CCcitsalpsyd,CHllamS
28
)rhT7331ell(.p
,AUS,RGUI,DSV,CPVP,sisenegsyd
metsysgnitcellocelbuod
DA
)ovoned(teh
)2SP,2MP,1SVP(P
;led702.c:2.730702_MN
21FCT
ylamonaenildiM
EPHlacipytA
38
)71*sfteM07ryT(.p
DA
)ovoned(teh
)2SP,5MP,1MP,2MP(P
;AAsniled786_686.c:5.942500_MN
1GXOF
niarbxelpmoC
,ailgnaglasablamronba,CCcitsalpsyD
78
)syL922elI(.p
DCMfosngis
DA
)ovoned(teh
)5PP,2PP,2MP,2SP(PL
;A>T863.c:4.034000_MN
1B1HAFAP
DCM
)ylahpecnessil(DCMfosngis,MVdliM
88
)syL321teM(.p
RA
tehpmoc
)2MP,1SVP(P
;led7941.c:2.225080100_MN
A2D2CC
metsysitluM
,syendikcitsycylop,elecolahpeC
98
)11*sfsyL005ulG(.p
dnasdnahfoylytcadyloplaixatsop
11.400000_CN
teef
led1+9714.c:)2.225080100_MN(
DA
)ovoned(teh
)2PP,3PP,2MP,2SP(PL
;G>A9374.c:4.958400_MN
CTLC
metsysitluM
fosngis,CCcitsalpsyd,ylahpecorciM
09
)ylG0851psA(.p
amedelasanerp,DCM
DA
)ovoned(teh
)2SP,2MP,1SVP(P
;led8361_7361.c:3.915710_MN
B1DIRA
niarbxelpmoC
,CHllams,sisenegaCC,MVereveS
19
)39*sfgrA645orP(.p
DCMfosngis,aisalpopyhralleberec
RLX
)tam(imeh
)4PP,2MP,1SVP(P
:)2.116300_MN(01.320000_CN
1DFO
metsysitluM
,DCMfosngis,MV,CHegraL
39
C>G1+7832.c
htootralom,aisalpopyhralleberec ,msiroletrepyh,CCcitsalpsyd,ngis
ylytcadyloplaixatsop,daeherofhgih teeffoylytcadyloplaixaerp,sdnahfo
DA
)ovoned(teh
)5PP,3PP,2MP,2SP(PL
;G>A6382.c:1.664391100_MN
1LSNAK
metsysitluM
,CCcitsalpsyd,SBdepahs-Z,MVdliM
49
)ylG649grA(.p
,aimlahthporcim,stibrolamronba
amyhcneraplanerralugerri
DA
)ovoned(teh
)2SP,5PP,2MP(PL
;G>A878.c:4.900600_MN
A1ABUT
niarbxelpmoC
,snrohlatnorflamronba,CCcitsalpsyD
79
)reS392nsA(.p
,ygolohpromSBlamronba
DCMfosngis,niarbcirtemmysa
.revodeunitnoC
© 2022TheAuthors.UltrasoundinObstetrics&GynecologypublishedbyJohnWiley&SonsLtd UltrasoundObstetGynecol2022;60:59–67.
onbehalfofInternationalSocietyofUltrasoundinObstetricsandGynecology.
ExomesequencinginfetuseswithCNSanomalies 65
deunitnoC2elbaT
ecnatirehnI
GMCAtnairaV
nrettap
ytisogyZ
noitacfiissalc
)s(tnairaV
eneG
yrogetaclacinilC
sgnidnfignigamI
esaC
DA
)ovoned(teh
)2SP,5PP,3PP,2MP(P
;A>G6802.c:6.548100_MN
1A4LOC
egamadniarB
thgir,ylahpecorcim,VIedarGHVI
601
)reS696ylG(.p
,noitpursidnrohlatnorf
CCdetpursid
DA
)ovoned(teh
)2SP,2MP,1SVP(P
A>T2+232.c:3.574240100_MN
L58PEC
DCM
CPVP,ylahpecnessiL
901
DA
)ovoned(teh
)5PP,2MP,1MP,2SP(P
;A>G7111.c:4.720500_MN
2R3KIP
niarbxelpmoC
,ylahpecorcam,sisenegsydCC
011
)grA373ylG(.p
DCMfosngis
RA
tehpmoc
/)5PP,2MP,1SVP(P
;T>C5791.c:6.407351_MN
76MEMT
metsysitluM
syendikcitsycitlum,elecolahpeC
111
)3MP,2MP,3SP(PL
-9821_61-9821.c/)*956grA(.p
)TTTTCled21
DA
)ovoned(teh
)4PP,1MP,2SP(PL
;C>T749.c:4.410871_MN
BBUT
niarbxelpmoC
cinoilgnag,sisenegaCC
211
)alA613laV(.p
snoiselecnenime
DA
)ovoned(teh
)2SP,2MP,1SVP(P
;T>C6811.c:6.548100_MN
1A4LOC
egamadniarB
VIedarGHVI
311
)*693grA(.p
deknil-X
)ovoned(teh
)3PP,2MP,2SP(PL
;C>A6811.c:6.984000_MN
XRTA
stsyclamydnepebuS
CPVP
411
)nlG693syL(.p
;ecnerefmucricdaeh,CH;musollacsuproc,CC;dnuopmoc,pmoc;metsniarb,SB;evissecerlamosotua,RA;tnanimodlamosotua,DA;scimoneGdnasciteneGlacideMfoegelloCnaciremA,GMCA fonoitamroflam,DCM;lanretam,tam;egahrromehralucirtnevartni,HVI;noitcirtserhtworgeniretuartni,RGUI;ylahpecnesorpoloh,EPH;suogyzomoh,moh;suogyzoreteh,teh;suogyzimeh,imeh deknil-X,DLX;tcefedlatpesralucirtnev,DSV;ylagemolucirtnev,MV;yretralacilibmuelgnis,AUS;stsycoduespralucirtnevirep,CPVP;lanretap,tap;tcefedebutlaruen,DTN;tnempolevedlacitroc
.evissecerdeknil-X,RLX;tnanimod
Table3Detectionrateofpathogenicandlikelypathogenic
variantsbychromosomalmicroarrayanalysis(CMA)andexome
sequencing(ES)among114caseswithfetalcentralnervoussystem
abnormality,accordingtoclinicalcategory
Clinicalcategory CMA ES
Multisystem 5/40(13) 14/32(44)
Complexbrain 5/32(16) 14/24(58)
MCD 0/11(0) 3/9(33)
Braindamage 0/14(0) 3/9(33)
Subependymal/arachnoidcysts 0/5(0) 1/4(25)
Midlineanomaly 0/4(0) 2/3(67)
MBHB 1/6(17) 0/3(0)
Neuraltubedefect 0/2(0) 1/2(50)
Total 11/114(10) 38/86(44)
Dataaregivenasn/N(%).MBHB,midbrain–hindbrain
malformation;MCD,malformationofcorticaldevelopment.
cases). Thus, the combined detection rate of ES for both
sequencevariantsandCNVswas50%.
DISCUSSION
In the postnatal setting, ES has demonstrated an
additional diagnostic yield for a variety of conditions of
25–45% beyond traditional methods. Multiple studies
have also shown the efficacy of ES in the prenatal
diagnosisofvariousfetalanomalies5–7,12,26–32.Inarecent
meta-analysis, the diagnostic yield for a variety of fetal
anomalies,regardlessoftheaffectedorgan,was9–47%33.
A higher rate was noted for fetuses showing multiple
malformations33. Several studies have reported that, in
cases with a CNS anomaly, the added diagnostic yield
is 3–34%6,7,12,18,30,34. Finally, there are only a handful
ofstudiesfocusingspecificallyonCNSanomalies,witha
diagnosticyieldrangingfrom19%to50%35–38.
In our study, the added diagnostic yield of ES
was 44%, with the highest yield observed in specific
subcategories (44% in multisystem and 58% in complex
brain anomalies). There was a non-significant trend
towardsahigherincidenceofmonogenicetiologyincases
with recurring brain anomalies compared with first-time
cases(63%vs39%;P=0.06).Therewasasignificantrisk
of recurrence in 53% of cases that had an ES diagnosis.
Thisinformationwillbeimportantforfuturereproductive
choices. Several participating couples have already opted
forpreimplantationgenetictesting(PGT).
In several cases with genetic etiology, we detected
P/LP variants in AR genes that were in concordance
with clinical manifestations. For example, Case 46 with
POMT1 variant and Case 50 with POMGNT2 variant
were suspected to have Walker–Warburg syndrome
(OMIM 236670, 614830) (Table2). However, in some
cases, clinical manifestations did not correspond to the
phenotype associated with the detected AR variants.
For example, pathogenic variants in VRK1 cause
pontocerebellar hypoplasia Type 1A (PCH1A, OMIM
607596), characterized postnatally by hypoplasia of the
ventralponsandcerebellumandneuronallossandgliosis
inthebrainstemandbasalganglia.However,prenatally,
Case 5 with a homozygous VRK1 variant exhibited
© 2022TheAuthors.UltrasoundinObstetrics&GynecologypublishedbyJohnWiley&SonsLtd UltrasoundObstetGynecol2022;60:59–67.
onbehalfofInternationalSocietyofUltrasoundinObstetricsandGynecology.
66 Yaronetal.
a dysplastic corpus callosum (CC), delayed sulcation Ourstudyhassomelimitations.First,ourseriesconsists
and cerebellar hypoplasia. This highlights the fact that ofhighlyselectedcasesthatweresevereenoughtowarrant
prenatal manifestations may differ and be more severe terminationofpregnancy.Thus,ourconclusionsmaynot
whencomparedwiththosedescribedpostnatally.Thereis applytoallbrainanomalies.Second,thestudywascarried
aneedtoexpandtheHPOterminologytoincludeaccurate out at a referral center for prenatal CNS anomalies and,
prenatal manifestations. Such efforts are currently being assuch,mayhavehadselectionbiasduetosevereand/or
undertaken by the Fetal Sequencing Consortium39. recurrentcasesbeingmorelikelytohavegeneticetiology.
Moreover, this suggests that accurate diagnoses cannot Third, conclusions regarding specific clinical subgroups
rely on imaging alone, and that sequencing information arelimitedowingtoarelativelysmallnumberofcasesin
providesadditionalimportantinsights. eachsubcategory.
As expected, of the 22 cases with an AD mode of In conclusion, we have shown that, in fetuses with
inheritance, 17 (77%) cases were de novo. Nonetheless, major CNS anomalies, ES has an additional diagnostic
consideration should be given to the five inherited AD yieldof44%overthe10%providedbyCMA.BecauseES
cases. In two maternally inherited cases, tubulinopathy canalsodetectmanyCNVsandgiventhetighttimeframe
was detected. In Case 3, a TUBB3 (OMIM 614039) LP in pregnancy, we suggest that ES should be considered
missense variant was detected in a fetus with cortical as a first-tier test in the prenatal diagnosis of major
dysplasia and abnormal sulcation. In Case 62, a TUBB CNS anomalies. Given the limited prenatal phenotype
(OMIM 615771) LP missense variant was found in a information, the additional prognostic information
fetus with CC hypoplasia, asymmetric hemispheres, ven- provided by ES is crucial for timely and evidence-based
triculomegaly,megacisternamagnaandcolpocephaly.In decision-making. Moreover, given that over half of the
Case 97, a de-novo LP missense variant in the TUBA1A causative variants are inherited, their detection by ES
gene (OMIM 611603) was found in a fetus with corti- providesvaluableinformationregardingtheriskofrecur-
cal dysplasia, abnormal cortical gyration and brainstem renceinsubsequentpregnanciesandfacilitatescounseling
abnormality. Pathogenic variants in the tubulin isotypes regardingreproductivechoices,suchasprenataldiagnosis
areassociatedwithvarioustypesofcomplexcorticaldys- or PGT. Further studies are needed to assess whether ES
plasia with other brain malformations. Perturbation of alonecouldbeusedforreliableCNVdetection.
the tubulins may be associated with a spectrum of neu-
rodevelopmentaldisorderswithincompletepenetrance40.
ACKNOWLEDGMENTS
InCase61,amaternallyinheritedDCC(OMIM157600)
loss-of-function variant was detected. On further exam-
The authors thank the families and referring physicians,
ination, the otherwise unaffected mother was found to
as well as our genetic counseling staff, including Dr
have mirror hand movements, a well-described phe-
Dalit Barel, Sharon Simchoni, Amit Wainstein, Shira
nomenonassociatedwiththisgene41.Thefetus,however,
Lotan Sultanik and Adi Botvinik. All genetic testing
was found to have partial agenesis of the CC, which
was performed as a clinical service under standard
is another known consequence of DCC mutations42.
clinical consent. The study was approved by the Tel
In Case 73, a paternally inherited COL4A2 (OMIM
AvivSouraskyMedicalCenterInstitutionalReviewBoard
614483) deletion was associated with Grade IV intra-
(No.0039-15-TLV).Retrospectivecollectionofdatafrom
ventricular hemorrhage (IVH) in the index fetus and
patient records has been granted a waiver of informed
in the fetus in a previously terminated pregnancy. The
consent, as all clinical data contained in this report have
carrier father had cerebral palsy (CP), most likely as a
beende-identified.Y.Y.isanadviserforGenoox(https://
consequenceofin-uteroIVH.Thefather’sniece,whoalso
www.genoox.com), developers of the Franklin pipeline
had CP, carried the same pathogenic variant. In Case
used for bioinformatics analysis. He was also a Clinical
40,thefetuspresentedwithChiariType-IImalformation
ExpertPanelmemberforIllumina(https://www.illumina
secondary to a neural tube defect. ES analysis revealed
.com), manufacturers of the NovaSeq 6000 used for
a maternally inherited stop codon in the SCRIB gene
exomesequencinginthisstudy.
(OMIM *607733). Variants in SCRIB and other planar
cell polarity genes have been associated with neural tube
defectsinanimals43andhumans44,45.Thehealthymother
REFERENCES
had no clinical signs of a neural tube defect. These cases
highlightthefactthatevenpathogenicvariantsmayhave 1. BestS,WouK,VoraN,VanderVeyverIB,WapnerR,ChittyLS.Promises,pitfalls
and practicalities of prenatal whole exome sequencing. Prenat Diagn 2018; 38:
variableexpressionandincompletepenetranceandstress 10–19.
the importance of obtaining a full medical history and 2. CallawayJL,ShafferLG,ChittyLS,RosenfeldJA,CrollaJA.Theclinicalutility
ofmicroarraytechnologiesappliedtoprenatalcytogeneticsinthepresenceofa
examiningotherfamilymembers. normalconventionalkaryotype:areviewoftheliterature.PrenatDiagn2013;33:
Inadditiontothe44%diagnosticyieldofP/LPvariants, 1119–1123.
3. WapnerRJ,MartinCL,LevyB,BallifBC,EngCM,ZacharyJM,SavageM,PlattLD,
nine(10%)othercaseshadaVOUSwithpotentialclinical SaltzmanD,GrobmanWA,KlugmanS,SchollT,SimpsonJL,McCallK,Aggarwal
relevance (TableS1). Such VOUSs may prove over time VS,BunkeB,NahumO,PatelA,LambAN,ThomEA,BeaudetAL,LedbetterDH,
ShafferLG,JacksonL.Chromosomalmicroarrayversuskaryotypingforprenatal
tobebenignorunrelatedtotheclinicalscenarioowingto diagnosis.NEnglJMed2012;367:2175–2184.
data-sharingtoolssuchasGeneMatcher46ortheFranklin 4. RobsonSC,ChittyLS,MorrisS,VerhoefT,AmblerG,WellesleyDG,GrahamR,
Leader C, Fisher J, Crolla JA. Evaluation of Array Comparative genomic
UsersCommunity47.
Hybridisationinprenataldiagnosisoffetalanomalies:amulticentrecohortstudy
© 2022TheAuthors.UltrasoundinObstetrics&GynecologypublishedbyJohnWiley&SonsLtd UltrasoundObstetGynecol2022;60:59–67.
onbehalfofInternationalSocietyofUltrasoundinObstetricsandGynecology.
ExomesequencinginfetuseswithCNSanomalies 67
withcostanalysisandassessmentofpatient,healthprofessionalandcommissioner withcongenitalanomaliesofthekidneyandurinarytract.NephrolDialTransplant
preferencesforarraycomparativegenomichybridisation.Southampton(UK):NIHR 2017;32:1665–1675.
JournalsLibrary;2017Feb. 27. Leung GKC, Mak CCY, Fung JLF, Wong WHS, Tsang MHY, Yu MHC, Pei
5. JelinAC,VoraN.WholeExomeSequencing:ApplicationsinPrenatalGenetics. SLC, Yeung KS, Mok GTK, Lee CP, Hui APW, Tang MHY, Chan KYK, Liu
ObstetGynecolClinNorthAm2018;45:69–81. APY,YangW,ShamPC,KanASY,ChungBHY.Identifyingthegeneticcauses
6. Lord J, McMullan DJ, Eberhardt RY, Rinck G, Hamilton SJ, Quinlan-Jones E, forprenatallydiagnosedstructuralcongenitalanomalies(SCAs)bywhole-exome
Prigmore E, Keelagher R, Best SK, Carey GK, Mellis R, Robart S, Berry IR, sequencing(WES).BMCMedGenomics2018;11:93.
Chandler KE, Cilliers D, Cresswell L, Edwards SL, Gardiner C, Henderson A, 28. MackieFL,CarssKJ,HillmanSC,HurlesME,KilbyMD.ExomeSequencingin
HoldenST,HomfrayT,LesterT,LewisRA,Newbury-EcobR,PrescottK,Quarrell FetuseswithStructuralMalformations.JClinMed2014;3:747–762.
OW,RamsdenSC,RobertsE,TaponD,TooleyMJ,VasudevanPC,WeberAP, 29. NormandEA,AlaimoJT,VandenVeyverIB.Exomeandgenomesequencingin
WellesleyDG,WestwoodP,WhiteH,ParkerM,WilliamsD,JenkinsL,ScottRH, reproductivemedicine.FertilSteril2018;109:213–220.
KilbyMD,ChittyLS,HurlesME,MaherER;PrenatalAssessmentofGenomes 30. NormandEA,BraxtonA,NassefS,WardPA,VetriniF,HeW,PatelV,QuC,
and Exomes Consortium. Prenatal exome sequencing analysis in fetal structural WesterfieldLE,StoverS,DharmadhikariAV,MuznyDM,GibbsRA,DaiH,MengL,
anomaliesdetectedbyultrasonography(PAGE):acohortstudy.Lancet2019;393: WangX,XiaoR,LiuP,BiW,XiaF,WalkiewiczM,VandenVeyverIB,EngCM,
747–757. YangY.Clinicalexomesequencingforfetuseswithultrasoundabnormalitiesanda
7. Petrovski S, Aggarwal V, Giordano JL, Stosic M, Wou K, Bier L, Spiegel E, suspectedMendeliandisorder.GenomeMed2018;10:74.
BrennanK,StongN,JobanputraV,RenZ,ZhuX,MebaneC,NahumO,WangQ, 31. VoraNL,PowellB,BrandtA,StrandeN,HardistyE,GilmoreK,ForemanAKM,
Kamalakaran S, Malone C, Anyane-Yeboa K, Miller R, Levy B, Goldstein DB, WilhelmsenK,BizonC,ReillyJ,OwenP,PowellCM,SkinnerD,RiniC,LyerlyAD,
WapnerRJ.Whole-exomesequencingintheevaluationoffetalstructuralanomalies: BoggessKA,WeckK,BergJS,EvansJP.Prenatalexomesequencinginanomalous
aprospectivecohortstudy.Lancet2019;393:758–767. fetuses:newopportunitiesandchallenges.GenetMed2017;19:1207–1216.
8. MonaghanKG,LeachNT,PekarekD,PrasadP,RoseNC,ACMGProfessional 32. Yates CL, Monaghan KG, Copenheaver D, Retterer K, Scuffins J, Kucera CR,
PracticeandGuidelinesCommittee.Theuseoffetalexomesequencinginprenatal FriedmanB,RichardG,JuusolaJ.Whole-exomesequencingondeceasedfetuses
diagnosis:apointstoconsiderdocumentoftheAmericanCollegeofMedicalGenetics withultrasoundanomalies:expandingourknowledgeofgeneticdiseaseduringfetal
andGenomics(ACMG).GenetMed2020;22:675–680. development.GenetMed2017;19:1171–1178.
9. TolussoLK,HazeltonP,WongB,SwarrDT.Beyonddiagnosticyield:prenatal 33. GuadagnoloD,MastromoroG,DiPalmaF,PizzutiA,MarchionniE.PrenatalExome
exomesequencingresultsinmaternal,neonatal,andfamilialclinicalmanagement Sequencing:Background,CurrentPracticeandFuturePerspectives–ASystematic
changes.GenetMed2021;13:1–9. Review.Diagnostics(Basel)2021;11:224.
10. RouleauC,GasnerA,BigiN,CoutureA,PerezMJ,BlanchetP,FaureJM,RivierF, 34. BoisselS,Fallet-BiancoC,ChitayatD,KremerV,NassifC,RypensF,DelrueMA,
Boulot P, Laquerrie`re A, Encha-Razavi F. Prevalence and timing of pregnancy DalSoglioD,OlignyLL,PateyN,FloriE,CloutierM,DymentD,CampeauP,
terminationforbrainmalformations.ArchDisChildFetalNeonatalEd2011;96: KaralisA,NizardS,FraserWD,AudibertF,LemyreE,RouleauGA,HamdanFF,
F360–F364. KibarZ,MichaudJL.Genomicstudyofseverefetalanomaliesanddiscoveryof
11. de Wit MC, Srebniak MI, Govaerts LC, Van Opstal D, Galjaard RJ, Go AT. GREB1Lmutationsinrenalagenesis.GenetMed2018;20:745–753.
Additionalvalueofprenatalgenomicarraytestinginfetuseswithisolatedstructural 35. WeitensteinerV,ZhangR,BungenbergJ,MarksM,GehlenJ,RalserDJ,HilgerAC,
ultrasound abnormalities and a normal karyotype: a systematic review of the SharmaA,SchumacherJ,GembruchU,MerzWM,BeckerA,AltmullerJ,ThieleH,
literature.UltrasoundObstetGynecol2014;43:139–146. HerrmannBG,OdermattB,LudwigM,ReutterH.Exomesequencinginsyndromic
12. FuF,LiR,LiY,NieZQ,LeiT,WangD,YangX,HanJ,PanM,ZhenL,OuY, brainmalformationsidentifiesnovelmutationsinACTB,andSLC9A6,andsuggests
LiJ,LiFT,JingX,LiD,LiaoC.Wholeexomesequencingasadiagnosticadjunctto BAZ1Aasanewcandidategene.BirthDefectsRes2018;110:587–597.
clinicaltestinginfetuseswithstructuralabnormalities.UltrasoundObstetGynecol 36. Heide S, Spentchian M, Valence S, Buratti J, Mach C, Lejeune E, Olin V,
2018;51:493–502. MassimelloM,LehalleD,MouthonL,WhalenS,FaudetA,MignotC,GarelC,
13. SongT,XuY,LiY,JiaL,ZhengJ,DangY,WanS,ZhengY,ZhangJ,YangH. Blondiaux E, Lefebvre M, Quenum-Miraillet G, Chantot-Bastaraud S, Milh M,
Detectionofsubmicroscopicchromosomalaberrationsbychromosomalmicroarray BretelleF,PortesVD,GuibaudL,PutouxA,TsatsarisV,SpodenkiewicM,LayetV,
analysisfortheprenataldiagnosisofcentralnervoussystemabnormalities.JClin Dard R, Mandelbrot L, Guet A, Moutton S, Gorce M, Nizon M, Vincent M,
LabAnal2020;34:e23434. Beneteau C, Rocchisanni MA, Benachi A, Saada J, Attie-Bitach T, Guilbaud L,
14. Malinger G, Paladini D, Haratz KK, Monteagudo A, Pilu GL, Timor-Tritsch MauriceP,FriszerS,JouannicJM,deVillemeurTB,MoutardML,KerenB,He´ronD.
IE. ISUOG Practice Guidelines (updated): sonographic examination of the fetal Prenatalexomesequencingin65fetuseswithabnormalityofthecorpuscallosum:
central nervous system. Part 1: performance of screening examination and contributiontofurtherdiagnosticdelineation.GenetMed2020;22:1887–1891.
indicationsfortargetedneurosonography.UltrasoundObstetGynecol2020;56: 37. LiL,FuF,LiR,XiaoW,YuQ,WangD,JingX,ZhangY,YangX,PanM,LiuZ,
476–484. LiaoC.Genetictestsaidincounselingoffetuseswithcerebellarvermisdefects.
15. RiggsER,AndersenEF,CherryAM,KantarciS,KearneyH,PatelA,RacaG,Ritter PrenatDiagn2020;40:1228–1238.
DI,SouthST,ThorlandEC,Pineda-AlvarezD,AradhyaS,MartinCL.Technical 38. TanH,XieY,ChenF,ChenM,YuL,ChenD,ChenJ.Novelandrecurrentvariants
standardsfortheinterpretationandreportingofconstitutionalcopy-numbervariants: identifiedinfetuseswithcentralnervoussystemabnormalitiesbytrios-medicalexome
ajointconsensusrecommendationoftheAmericanCollegeofMedicalGeneticsand sequencing.ClinChimActa2020;510:599–604.
Genomics(ACMG)andtheClinicalGenomeResource(ClinGen).GenetMed2020; 39. https://www.columbiaobgyn.org/fetal-sequencing-consortium.
22:245–257. 40. BreussM,HengJI-T,PoirierK,TianG,JaglinXH,QuZ,BraunA,GstreinT,NgoL,
16. http://genome.ucsc.edu/cgi-bin/hgGateway. HaasM,Bahi-BuissonN,MoutardM-L,PassemardS,VerloesA,GressensP,XieY,
17. http://dgv.tcag.ca/dgv/app/home. RobsonKJH,RaniDS,ThangarajK,ClausenT,ChellyJ,CowanNJ,KeaysDA.
18. RechesA,HierschL,SimchoniS,BarelD,GreenbergR,BenSiraL,MalingerG,
Mutationsintheβ-tubulingeneTUBB5causemicrocephalywithstructuralbrain
Yaron Y. Whole-exome sequencing in fetuses with central nervous system abnormalities.CellRep2012;2:1554–1562.
abnormalities.JPerinatol2018;38:1301–1308. 41. SrourM,Rivie`reJ-B,PhamJMT,Dube´M-P,GirardS,MorinS,DionPA,AsselinG,
19. LiH,DurbinR.FastandaccurateshortreadalignmentwithBurrows–Wheeler Rochefort D, Hince P, Diab S, Sharafaddinzadeh N, Chouinard S, The´oret H,
transform.Bioinformatics2009;25:1754–1760. CharronF,RouleauGA.MutationsinDCCcausecongenitalmirrormovements.
20. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Science2010;328:592.
GarimellaK,AltshulerD,GabrielS,DalyM,DePristoMA.TheGenomeAnalysis 42. Spencer-Smith M, Knight JL, Lacaze E, Depienne C, Lockhart PJ, Richards LJ,
Toolkit:aMapReduceframeworkforanalyzingnext-generationDNAsequencing Heron D, Leventer RJ, Robinson GA. Callosal agenesis and congenital mirror
data.GenomeRes2010;20:1297–1303. movements: outcomes associated with DCC mutations. Dev Med Child Neurol
21. GarrisonE,MarthG.Haplotype-basedvariantdetectionfromshort-readsequencing. 2020;62:758–762.
http://arXiv.org/abs/1207.3907. 43. Murdoch JN, Henderson DJ, Doudney K, Gaston-Massuet C, Phillips HM,
22. https://help.genoox.com/en/articles/5365431-rainbow-cnv-detection-by-franklin. PaternotteC,ArkellR,StanierP,CoppAJ.Disruptionofscribble(Scrb1)causes
23. RichardsS,AzizN,BaleS,BickD,DasS,Gastier-FosterJ,GrodyWW,HegdeM, severeneuraltubedefectsinthecircletailmouse.HumMolGenet2003;12:87–98.
LyonE,SpectorE,VoelkerdingK,RehmHL;ACMGLaboratoryQualityAssurance 44. LeiY,ZhuH,DuhonC,YangW,RossME,ShawGM,FinnellRH.Mutationsin
Committee.Standardsandguidelinesfortheinterpretationofsequencevariants:a planarcellpolaritygeneSCRIBareassociatedwithspinabifida.PLoSOne2013;8:
jointconsensusrecommendationoftheAmericanCollegeofMedicalGeneticsand e69262.
GenomicsandtheAssociationforMolecularPathology.GeneticMed2015;17: 45. RobinsonA,EscuinS,DoudneyK,VekemansM,StevensonRE,GreeneND,Copp
405–424. AJ,StanierP.MutationsintheplanarcellpolaritygenesCELSR1andSCRIBare
24. https://hpo.jax.org/app/. associatedwiththesevereneuraltubedefectcraniorachischisis.HumMutat2012;
25. https://www.socscistatistics.com. 33:440–447.
46. https://genematcher.org.
26. LeiT-Y,FuF,LiR,WangD,WangR-Y,JingX-Y,DengQ,LiZ-Z,LiuZ-Q,
47. https://franklin.genoox.com.
YangX,LiD-Z,LiaoC.Whole-exomesequencingforprenataldiagnosisoffetuses
SUPPORTING INFORMATION ON THE INTERNET
Thefollowingsupportinginformationmaybefoundintheonlineversionofthisarticle:
TableS1Caseswithvariantsofuncertainsignificance(VOUS)detectedbyexomesequencing(ES)among86casesoffetalCNSanomalies
TableS2Caseswithnegativeexomesequencing(ES)resultsamong86casesoffetalCNSanomalies
© 2022TheAuthors.UltrasoundinObstetrics&GynecologypublishedbyJohnWiley&SonsLtd UltrasoundObstetGynecol2022;60:59–67.
onbehalfofInternationalSocietyofUltrasoundinObstetricsandGynecology.
